Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CMO Robert Iannone sold 7,080 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $138.60, for a total transaction of $981,288.00. Following the sale, the chief marketing officer now owns 82,024 shares in the company, valued at $11,368,526.40. This trade represents a 7.95 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Jazz Pharmaceuticals Stock Performance
JAZZ traded up $2.36 on Friday, reaching $138.81. The company had a trading volume of 1,226,548 shares, compared to its average volume of 763,953. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $148.06. The stock has a market capitalization of $8.43 billion, a PE ratio of 19.55, a P/E/G ratio of 1.04 and a beta of 0.44. The stock has a 50-day moving average price of $128.14 and a 200-day moving average price of $120.03.
Wall Street Analysts Forecast Growth
JAZZ has been the subject of several research reports. Cantor Fitzgerald downgraded shares of Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and boosted their price target for the stock from $140.00 to $150.00 in a research note on Wednesday, February 26th. UBS Group upgraded Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their target price for the company from $145.00 to $179.00 in a report on Friday. Royal Bank of Canada cut their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an "outperform" rating on the stock in a report on Wednesday, February 26th. Barclays reaffirmed an "overweight" rating and issued a $200.00 price target (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Finally, HC Wainwright restated a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $189.40.
View Our Latest Report on Jazz Pharmaceuticals
Institutional Trading of Jazz Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in JAZZ. IFP Advisors Inc acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC grew its position in shares of Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 101 shares during the last quarter. Elequin Capital LP increased its holdings in shares of Jazz Pharmaceuticals by 677.8% in the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after acquiring an additional 183 shares during the period. CoreFirst Bank & Trust acquired a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at $28,000. Finally, Allianz SE purchased a new stake in Jazz Pharmaceuticals in the 4th quarter valued at $29,000. 89.14% of the stock is owned by hedge funds and other institutional investors.
Jazz Pharmaceuticals Company Profile
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Read More
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
